Webinar

Solving common drug discovery challenges with the latest Artificial Intelligence and Large Language Models

July 10, 2025 03:30 PM Europe/London

Pharma and biotech in 2025 face greater business pressures than ever before to improve  clinical success rates and reduce costs. 

Artificial Intelligence and Large Language Model technologies present a unique opportunity in drug discovery and early R&D; more accurate and reliable data-driven hypothesis generation underpins better decisions for experimental validation and clinical testing, accelerating success rates and cycle times.

This webinar will address the key business and research successes with AI from teams across large pharma and smaller biotechs, with exciting new insights and impactful examples.

 

There will be an interactive Q&A with a distinguished panel of data science leaders as well as keynote talks diving into specific case studies.

Register for free to attend the live webinar. Registering will also grant you early access to the webinar recording, even if you can’t make it on the day>> https://webinars.biorelate.com/solving-common-drug-discovery

Learn more about Biorelate by following us on LinkedIn: https://www.linkedin.com/company/biorelate-limited/

And visiting www.biorelate.com 

Ben Sidders

Chief Scientific Officer, Biorelate

Dr Ben Sidders, Chief Scientific Officer at Biorelate, has been working at the forefront of pharma data science for the last two decades. Formerly Executive Director and Head of Early Data Science within Oncology R&D at AstraZeneca, responsible for advancing the company’s understanding of disease through computational oncology, Ben also previously spent eight years at Pfizer, and has extensive experience of many aspects of drug discovery for major pharma. He is especially passionate about immuno-oncology, network biology and the role of bioinformatics within drug discovery. Ben has a PhD in Molecular Biology & Bioinformatics from the University of London where his thesis focused on the development of predictive markers for the diagnosis of asymptomatic Tuberculosis. He holds patents for two clinical diagnostics and has authored over 30 scientific publications.

Add to calendar

Ask a question

Ask as (log out)